Skip to main content
Petri Dish

101 College Street Rendering
101 College St. Rendering

100 College Street was the first of two towers slated for the developable land created by the Downtown Crossing Project. Currently, 100 College St (500,000 sq. ft.) is fully occupied by researchers from Alexion and Yale University.

Winstanley Enterprises has begun construction on the second bioscience tower at 101 College St. This is in response to the growing demand and to further connect the medical district and downtown area.

There are also other notable construction projects in the works, including 275 South Orange Street (planned construction in 20234, opening in 2026, and spanning 250,000 sq. ft.), Parcel B at Downtown Crossing (with an available site of 200-500,000 sq. ft.), and Science Park (with an available site of 200,000 sq. ft.).

LIFE SCIENCE

2nd Largest Bioscience Hub in New England

Greater New Haven has emerged as a thriving hub for life sciences, attracting a growing number of biotech companies. The region has become the preferred choice of 46% of the 112 biotech companies in Connecticut due to its robust ecosystem that fosters innovation and progress in the field.

The region has consistently attracted substantial investment in research and development, exemplified by the National Institute of Health investing $636 million in the sector in 2023. This investment has been instrumental in accelerating the life sciences industry's growth in Greater New Haven.

Several startups have been developed from Yale University's cutting-edge academic research in life sciences, biotechnology, and digital health. The Yale School of Medicine and Yale Ventures are vital in advancing biotech research into the commercial space. The list of companies launched at Yale includes Proteowise Inc., Arvinas, IsoPlexis Corporation, NextCure, Cybrexa Therapeutics Inc., Halda Therapeutics, Allyx Therapeutics, Biohaven Pharmaceutical, and Alexion Pharmaceuticals.

The region's appeal as a center for innovation is further bolstered by its strategic location, which provides easy access to major research institutions, academic centers, and a highly skilled workforce. World-class research facilities and top-notch talent have made Greater New Haven an ideal destination for biotech companies looking to establish themselves in the region.

Milestone/Accomplishments

  • Paris-based ReST Therapeutics and Heidelberg-based BioMed X have both chosen New Haven as the site for their U.S. headquarters and biomedical research institute, respectively. This influx of foreign companies further solidifies Greater New Haven's reputation as a magnet for top-tier scientific endeavors.
  • Breakthrough advancements in healthcare technology from local companies, such as Butterfly Network's FDA-cleared AI-enabled lung tool, underscore the region's commitment to pioneering solutions that redefine medical diagnostics and treatment.
  • Significant development projects in the region include the 500,000 sq. ft. med/lab building, 101 College Street, which is currently under construction and set to open in 2024. This building will also include 30,000 sq. ft. of incubator space. The 250,000 sq. ft. med/lab building, 275 South Orange Street, has also been approved for a 2026 opening.

RESOURCES

BioCT: 203 470 2720